Uncategorized

Oncology/Autoimmune – June 23 | Summer showcase 2022

Company介绍Intro
ViGenCellViGenCell Inc.是一家开发免疫细胞治疗技术的医药公司。目前有三个针对肿瘤学和免疫抑制的细胞治疗平台。1. 细胞毒性T淋巴细胞(CTL)技术,使用自体T细胞产生抗原特异性杀伤性T细胞,用于治疗血液恶性肿瘤;2.异体γδT(γδT)细胞,针对血液病和实体癌;3. 髓源性抑制细胞,可用来治疗自身免疫性疾病。ViGenCell is a company specialized in immune cell therapy. We currently have three cell therapy platforms targeting oncology and immunosupression. 1. Cytotoxic T Lymphocyte (CTL) technology that uses autologous T cells to produce antigen-specific killer T cells for hematological malignancies,  2.  allogenic γδT (Gamma Delta T) cells (naive & CAR engineered) targeting both hematological and solid cancers, and 3. Cord Blood Derived Myeloid Suppressor (CBMS) cells targeting autoimmune diseases.
Genhouse Bio勤浩医药是一家专注于专注于全球领先的小分子抗肿瘤新药开发的生物科技公司。勤浩医药建立了基于结构生物学的构效关系研究平台。勤浩医药形成了以靶向抗肿瘤品种为核心的产品管线,并将其SHP2抑制剂GH21的中国境外权利授权给一家国际生物技术公司HUYABIO。勤浩医药将继续推进更多的创新管线项目进入开发。Genhouse Bio is a clinical-stage biotech company focusing on the development of global next-generation anti-cancer therapeutics. Genhouse has established intergrated in-house drug development platforms. With these platforms, Genhouse has started to build a highly innovative anti-cancer pipeline and out-licensed the ex-China rights of its SHP2 inhibitor GH21 to HUYABIO , an international biotech company. Genhouse will continue to advance more innovative pipeline programs into global development.
Enduring Biotech 康源久远致力于开发具有临床优势的差异化抗体技术和创新型生物新药 是一家专注于癌症治疗和自身免疫型慢性炎症疾病的创新抗体药物研发企业。产品管线基于专利双位点特异性聚乙二醇技术(DSP),形成了一个强大的处于不同开发阶段的研究性疗法组合。Shenzhen Enduring Biotech TD (SZEB, or KYJY) is a research-based biotech established by accomplished scientists of drug PEGylation. Our heritage of science, curiosity and passion has enabled us to develop innovative therapies to fight life threatening diseases. Built on our patented double-site-specific pegylation technology (DSP), our pipeline forms a robust portfolio of investigational therapies at varied development stages.
Xuanzhu Biopharm轩竹生物是一家国际性的创新药物研究与开发企业。我们致力于七个前沿治疗领域,以强大的肿瘤、代谢和心血管疾病的产品管线,打造中国创新药物的顶级领导者。Xuanzhu Biopharm is an inernational research and development (R&D) enterprise of innovative drugs. We work on seven cutting-edge therapeutic areas, building a top leader in Chinese innovative drugs with powerful R&D pipelines for oncology, metabolism and cardiovascular diseases.
Immunophage Biotech成立于2016 年,标的公司是一家专注于开发用于 治疗恶性肿瘤、自身免疫性疾病、神经退行性疾病等疾病的创新药研发公司。公司所有在研产品均为自研 First in class 药物具有全新的抗体结构或全新的化合物结构 。其中2个创新靶点为全球首家唯一获批临床的产品。MIF抑制剂是全球进展最快的临床阶段产品,适应症覆盖肿瘤,自免和ND。CCR8 单抗是全球唯一一款强效拮抗并有一定ADCC的单抗药物,处于全球第一梯队。全球创新的GPCR小分子拮抗剂,靶点为 EB 病毒诱导的基因,是首个针对该靶点开发的Th17小分子抑制剂。Established in 2016, Immunophage focuses on immune regulation, discovering new targets and signaling pathways to precisely regulate the immune system, and providing the potentially best treatment options for malignant tumor, autoimmune diseases, neurodegenerative diseases and metabolic diseases. All the assets under development are first-in-class and have filed new chemical structure or new antibody structure patents. Their lead assets that target MIF and CCR8 are the most advanced in clinical development.
MIF inhibitor is the most advanced first-in-class clincal stage product. CCR8 nonoclonal antibody is potenly antagonizes CCR8 and has ADCC effect, which is highly differentiated compare to other competitors.
Nanjing Chuangte南京创特成立于2019年,是一家专门从事新药研发及产品产业化的传新型生物医药企业,聚焦肿瘤,脑血管及呼吸系统疾病,致力于通过创新驱动医药产业资源的整合。其先导资产为选择性抑制EGFR突变蛋白的三代抗肿瘤产品,临床适应症为一线治疗EGFR激活型非小细胞肺癌,二线治疗EGFR T790突变的非小细胞肺癌,目前正在进行三期临床,预计2023年NDA。Founded in February 2019,Chuangte is an innovative biotechnology company specializing in the research and development of new drugs, technology transfer and industrialization of new pharmaceutical products, targeting for oncology, cerebrovascular and respiratory diseases. Their lead asset is the third generation TKI which selectively inhibits EGFR mutations, especially T790M mutation. First line EGFR positive advanced NSCLC; Second line EGFR T790M mutation positive NSCLC. Ph3 is ongoing and NDA is expected in 2023.
Medivir ABMedivir公司开发创新药物,重点是医疗需求较高的癌症。这些候选药物针对的是现有疗法有限或缺失的适应症领域,并且有很大的机会为患者提供显著的改善。候选药物针对的是现有疗法有限或缺失的适应症领域,有很大的机会为患者提供重大的改善。Medivir正专注于开发 fostroxacitabine bralpamide (fostrox),该药物是一种选择性地治疗肝癌细胞并尽量减少副作用的原药,尽量减少副作用。Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 
OS TherapiesOS Therapies 是一家处于临床阶段的治疗公司,专注于骨肉瘤(OS)和其他实体肿瘤治疗方法的鉴定、开发和商业化。OS Therapies有两项针对实体瘤的平台技术。OST-HER2 PhIIb免疫肿瘤学以防止转移,以及OST-TDC作为下一代可调药物偶联物,带有ph值可变的SiLinkers和条件性活性有效载荷CAPs。OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies has two platform technologies targeting solid tumors: OST-HER2 PhIIb immuno-oncology to prevent metastasis, and OST-TDC pre-clinical next generation Tunable Drug Conjugate with ph-variable SiLinker linkers and multiple Conditionally Active Payloads (CAPs).
Shanghai Huaota Biopharmaceutical华奥泰生物药业已经建立了全面和综合的平台来开发新型生物制品。华奥泰生物药业的研发平台支持识别和开发新的单克隆抗体、双特异性抗体、融合蛋白、ADC药物等。华奥泰生物药业拥有多样化的产品管道,涵盖肿瘤和自身免疫性疾病等治疗领域。目前,有超过二十个项目正在开发中。其中许多项目已获得IND批准,并在美国、新西兰和中国进行多项临床试验。Huaota has built comprehensive and integrated platforms to develop novel biologics. The R&D platform at Huaota supports identifying and developing new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc. Huaota has a diverse product pipeline covering therapeutic areas such as tumors and autoimmune diseases. At present, there are over twenty projects under development. Many of them have obtained IND approval and multiple clinical trials are undertaken in the United States, New Zealand, and China. 
HanchorBio HanchorBio Group, established in November 2020, is a biotech company developing a multifunctional FBDB®-based fusion protein platform by its founder, former CEO of Helius, Dr. Shi-Kau Liu, with teams in Taiwan, China and worldwide for preclinical R&D. HanchorBio is dedicated to helping patients with immunotherapy-resistant tumors and has also developed several immunotherapy and cytokine drugs simultaneously. 
Aston Sci.Aston Sci.是一家临床阶段的生物制药公司,专注于各种治疗性癌症疫苗的基础研究和临床开发,总部设在韩国首尔。我们是一家以创新为导向的生物技术公司,在全球治疗性癌症疫苗行业中拥有丰富的科学资产。我们有华盛顿大学和Epithany Inc.作为战略研发伙伴,在癌症免疫治疗领域的当前和未来的癌症疫苗资产。  Aston Science is a clinical stage biopharmaceutical company focusing on basic research and clinical development for various therapeutic cancer vaccines, headquartered in Seoul, Korea. We are an innovative-oriented biotech have rich scientific assets among therapeutic cancer vaccine industry around the world. And we have University of Washington and Epithany Inc. as strategic R&D partners for current and upcoming cancer vaccine assets in the cancer immunotherapy field.